Plain-English fact sheet
MOTS-c
Also known as MOTS-c peptide, mitochondrial ORF of 12S rRNA type-c
MOTS-c is made from a small mitochondrial gene and has promising animal and cell research, while direct human treatment evidence and safety data are essentially absent.
Quick answer
MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, exercise adaptation, and aging biology. It is not FDA approved, and FDA reports no identified human exposure data for drug products containing MOTS-c.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and produced as part of cellular stress and metabolic signaling.
Studies measuring natural MOTS-c levels in people are not treatment trials, and a synthetic analog such as CB4211 is not interchangeable with native MOTS-c.
Why are people interested in it?
Animal studies report effects on insulin sensitivity, metabolic stress, physical capacity, and age-related decline.
Those findings have fueled 'exercise mimetic' and longevity claims that go far beyond direct human intervention evidence.
Current regulatory status
No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Metabolic disease and fatty-liver research
- Exercise and muscle-function biology
- Healthy-aging mechanisms
Evidence snapshot
Most treatment claims come from cells and animals. Human studies largely measure naturally circulating MOTS-c or response to exercise rather than test MOTS-c as a therapy.
Potential benefits being researched
- Animal studies report improved insulin sensitivity and physical capacity under selected experimental conditions.
- Human observational work shows associations with exercise and muscle measures, but association does not prove that administering MOTS-c produces a benefit.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA identifies potential immune reactions and complexities involving peptide impurities and active-ingredient characterization.
- There is no adequate human treatment dataset from which to estimate common, uncommon, or long-term harms.
- Unapproved products add identity, purity, sterility, strength, and labeling risks.
What we still do not know
- Whether administered MOTS-c produces any meaningful human metabolic or performance benefit
- Short- and long-term human safety
- How synthetic products compare with the naturally produced peptide
- Whether animal longevity or exercise findings translate to people
Plain-English takeaway
MOTS-c is compelling mitochondrial biology, not a proven exercise or longevity treatment. The missing step is direct, controlled human evidence with a characterized product.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2MOTS-c metabolism and insulin-sensitivity study
Preclinical study in animal models; it does not establish a human treatment effect.
- 3Human exercise study of mitochondrial-derived peptides
Study of naturally circulating peptide levels after exercise, not administration as a therapy.
- 4ClinicalTrials.gov: CB4211 Phase 1 study
Completed early trial of a MOTS-c analog; the registry has no posted results and the analog is not native MOTS-c.